Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 28474864)

  • 21. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.
    Arriola E; Cañadas I; Arumí-Uría M; Dómine M; Lopez-Vilariño JA; Arpí O; Salido M; Menéndez S; Grande E; Hirsch FR; Serrano S; Bellosillo B; Rojo F; Rovira A; Albanell J
    Br J Cancer; 2011 Sep; 105(6):814-23. PubMed ID: 21847116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
    Kentsis A; Reed C; Rice KL; Sanda T; Rodig SJ; Tholouli E; Christie A; Valk PJ; Delwel R; Ngo V; Kutok JL; Dahlberg SE; Moreau LA; Byers RJ; Christensen JG; Vande Woude G; Licht JD; Kung AL; Staudt LM; Look AT
    Nat Med; 2012 Jul; 18(7):1118-22. PubMed ID: 22683780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
    Nishimura Y; Hyuga S; Takiguchi S; Hyuga M; Itoh K; Hanawa T
    Int J Oncol; 2016 May; 48(5):1895-906. PubMed ID: 26983447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
    Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
    Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
    Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
    J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma.
    Imura Y; Nakai T; Yamada S; Outani H; Takenaka S; Hamada K; Araki N; Itoh K; Yoshikawa H; Naka N
    Cancer Sci; 2016 Dec; 107(12):1867-1876. PubMed ID: 27779808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
    Maulik G; Madhiwala P; Brooks S; Ma PC; Kijima T; Tibaldi EV; Schaefer E; Parmar K; Salgia R
    J Cell Mol Med; 2002; 6(4):539-53. PubMed ID: 12611639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Research progress of HGF/MET signaling pathway in EGFR-TKI resistance 
in non-small cell lung cancer].
    Song S; Bi M
    Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):755-9. PubMed ID: 25342043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer.
    Shi W; Song J; Wang W; Zhang Y; Zheng S
    Mol Med Rep; 2017 Nov; 16(5):7329-7336. PubMed ID: 28944826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
    Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
    Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
    Steinway SN; Dang H; You H; Rountree CB; Ding W
    PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.